


Please type a plus sign (+) inside this box → Approved for use through 10/31/2002. OMB 0651-0032  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>UTILITY PATENT APPLICATION TRANSMITTAL</b> <small>(Only for new nonprovisional applications under 37 CFR 1.53(b))</small>		Attorney Docket No. <b>NEURO 101 US</b>	
		First Inventor <b>Jean Rapin, et al.</b>	
		Express Mail Label No. <b>EV330777131US</b>	
<b>Title</b> <i>Tripeptide and Tripeptide Derivatives for the Treatment of Neuro-degenerative Diseases</i>			
<b>Application Elements</b> <small>See MPEP chapter 600 concerning utility patent application contents.</small>		<b>ADDRESS TO:</b> Commissioner of Patents Mail Stop Patent Application PO BOX 1450 Alexandria, VA 22313-1450	
1. <input checked="" type="checkbox"/> <b>Fee Transmittal Form</b> <small>(Submit an original, and a duplicate for fee processing)</small>		8. <input type="checkbox"/> CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix)	
2. <input type="checkbox"/> Applicant claims small entity status. <small>See 37 CFR 1.27</small>		9. Nucleotide and/or Amino Acid Sequence Submission <small>(if applicable, all necessary)</small>	
3. <input checked="" type="checkbox"/> <b>Specification</b> [Total Pages <b>49</b> ] <small>(preferred arrangement set forth below)</small> <ul style="list-style-type: none"> <li>- Descriptive title of the invention</li> <li>- Cross Reference to Related Applications</li> <li>- Statement Regarding Fed sponsored R &amp; D</li> <li>- Reference to sequence listing, a table, or a computer program listing appendix</li> <li>- Background of the Invention</li> <li>- Brief Summary of the Invention</li> <li>- Brief Description of the Drawings (if filed)</li> <li>- Detailed Description</li> <li>- Claim(s)</li> <li>- Abstract of the Disclosure</li> </ul>		a. <input type="checkbox"/> Computer Readable Form (CRF) b. Specification Sequence Listing on: i. <input type="checkbox"/> CD-ROM or CD-R (2 copies); or ii. <input type="checkbox"/> paper c. <input type="checkbox"/> Statement verifying identity of above copies	
4. <input checked="" type="checkbox"/> <b>Drawing(s)</b> (35 U.S.C. 113) [Total Pages <b>1</b> ] 5.		<b>ACCOMPANYING APPLICATION PARTS</b>	
6. <b>Oath or Declaration</b> [Total Pages <b>8</b> ] a. <input type="checkbox"/> Newly executed (original or copy) b. <input checked="" type="checkbox"/> Unexecuted c. <input type="checkbox"/> Copy from prior application (37 CFR 1.63(d)) <small>(for continuation/divisional with Box 17 completed)</small> i. <input type="checkbox"/> <b>DELETION OF INVENTOR(S)</b> <small>Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).</small>		10. <input type="checkbox"/> Assignment Papers (cover sheet & document(s)) 11. <input type="checkbox"/> 37 CFR 3.73(b) Statement <small>(when there is an assignee)</small> <input type="checkbox"/> Power of Attorney 12. <input type="checkbox"/> English Translation Document <small>(if applicable)</small> 13. <input type="checkbox"/> Information Disclosure Statement (IDS)/PTO-1449 <input type="checkbox"/> Copies of IDS Citations 14. <input checked="" type="checkbox"/> Preliminary Amendment 15. <input checked="" type="checkbox"/> Return Receipt Postcard (MPEP 503) <small>(Should be specifically itemized)</small> 16. <input type="checkbox"/> Certified Copy of Priority Document(s) <small>(if foreign priority is claimed)</small> 17. <input type="checkbox"/> Nonpublication Request under 35 U.S.C. 122 (b)(2)(B)(i). Applicant must attach form PTO/SB/35 or its equivalent. 18. <input checked="" type="checkbox"/> Other: check for \$ <b>750.00</b>	
7. <input type="checkbox"/> Application Data Sheet. See 37 CFR 1.76			
19. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76: <input checked="" type="checkbox"/> Continuation <input type="checkbox"/> Divisional <input type="checkbox"/> Continuation-in-part (CIP) of prior application No: PCT Application No. PCT/EP02/01180			
For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.			
<b>20. CORRESPONDENCE ADDRESS</b>			
<input checked="" type="checkbox"/> Customer Number or Bar Code Label		20786 <small>(Insert Customer No. or Attach bar code label here)</small>	
		OR <input checked="" type="checkbox"/> Correspondence address below	
Firm or Individual Name	Sherry M. Knowles, Esq. (Registration No. 33,052)		
Address	King & Spalding 191 Peachtree Street		
City	Atlanta	State	GA
Country	U.S.A.	Telephone	404-572-3541
		ZIP	30303-1763
		Fax	404-572-5145
Name (Print Type): Sherry M. Knowles		Registration No. (Attorney/Agent) 33,052	
Signature <i>Sherry M. Knowles</i>		Date August 5, 2003	

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Mail Stop Patent Application, PO Box 1450, Alexandria, VA 22313-1450.

 17497 U.S. PTO  
 10/635797  
 08/05/03

08/05/03  
1610  
S.

# FEE TRANSMITTAL

This sheet accompanies a patent application transmittal for the following application:

Inventor(s): Jean Rapin, et al.  
 Filing Date: August 5, 2003  
 Title: Tripeptide and Tripeptide Derivatives for the Treatment of Neuro-degenerative Diseases

The filing fee is calculated as shown below:

## 1. FILING FEE:

FOR:	SMALL ENTITY		LARGE ENTITY	
	FEE	FEE PAID	FEE	FEE PAID
<input checked="" type="checkbox"/> UTILITY FILING FEE	\$370.00		\$750.00	<b>\$750.00</b>
<input type="checkbox"/> DESIGN FILING FEE	\$165.00		\$330.00	
<input type="checkbox"/> PLANT FILING FEE	\$255.00		\$510.00	
<input type="checkbox"/> REISSUE FILING FEE	\$370.00		\$740.00	
<input type="checkbox"/> PROVISIONAL FILING FEE	\$80.00		\$160.00	
SUBTOTAL (1)				<b>\$750.00</b>

## 2. CLAIMS:

FOR:	NO. FILED	NO. EXTRA	SMALL ENTITY		LARGE ENTITY	
			RATE	FEE	RATE	FEE
TOTAL CLAIMS	16-20 =		x \$9 =	\$	x \$18 =	0
INDEP. CLAIMS	2- 3 =		x \$42 =	\$	x \$84 =	0
<input checked="" type="checkbox"/> MULTIPLE DEPENDENT CLAIM PRESENTED			+\$140 =	\$	+\$280 =	<b>\$ 280.00</b>
SUBTOTAL (2)				\$		<b>\$ 280.00</b>

## 3. ADDITIONAL FEES:

FOR:	SMALL ENTITY		LARGE ENTITY	
	FEE	FEE PAID	FEE	FEE PAID
<input type="checkbox"/> LATE FILING, FEE OR OATH	\$65		\$130	
<input type="checkbox"/> NON-ENGLISH SPECIFICATION	\$130		\$130	
<input type="checkbox"/> OTHER				
SUBTOTAL (3)		\$		

TOTAL FILING FEES: \$ 1300.00

A check is enclosed for the amount: \$ 750.00

☒ Charge any additional fees required under 37 C.F.R. 1.16 or 1.17 to Deposit Account 11-0980

KING & SPALDING

45<sup>th</sup> Floor, 191 Peachtree Street, N.E.

Atlanta, Georgia 30303

Telephone: 404.572.4600

By: Sherry Knowles / HORNE VU Date: August 5, 2003

Sherry M. Knowles, Esq.


Reg. No. 33,052

*in express permission*  
47,158

## UTILITY PATENT APPLICATION FILING

### Certificate of Mailing Under 37 CFR 1.10

I hereby certify that this Utility Patent Application and Transmittal, along with any documents referred to as attached therein are being deposited with the United States Postal Service in an envelope as "Express Mail Post Office to Addresses" services under 37 CFR 1.10, Mailing Label Number EV330777131US addressed to mail Stop Patent Application, Commissioner for Patents, PO Box 1450, Alexandria VA 22313-1450.

  
\_\_\_\_\_  
Hoang M. Vo

Date: August 5, 2003  
NEURO 101